ANDA 212610, held by Zhejiang Yongtai. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 212610 (Doxycycline Hyclate), held by Zhejiang Yongtai, was first approved by FDA on Mar 31, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 31, 2020 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 50MG BASE · capsule;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 100MG BASE · capsule;oral | Doxycycline Hyclate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters